levofloxacin has been researched along with abemaciclib in 1 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (abemaciclib) | Trials (abemaciclib) | Recent Studies (post-2010) (abemaciclib) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 352 | 43 | 343 |
| Protein | Taxonomy | levofloxacin (IC50) | abemaciclib (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.0734 | |
| Cyclin-K | Homo sapiens (human) | 0.065 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.7586 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.62 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0097 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.7484 | |
| Cyclin-A2 | Homo sapiens (human) | 0.1036 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0048 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.232 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.1847 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0112 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 2.027 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0693 | |
| Cyclin-H | Homo sapiens (human) | 2.6027 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 3.106 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.0168 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.405 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.405 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
1 review(s) available for levofloxacin and abemaciclib
| Article | Year |
|---|---|
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |